Pritumumab is a natural, fully human monoclonal antibody (IgG1 kappa) developed as an anti-cancer therapeutic. Its primary mechanism of action is the specific recognition and high-affinity binding to a cell-surface-expressed form of vimentin, particularly the ectodomain variant known as ecto-domain vimentin (EDV). Vimentin, an intermediate filament protein typically located inside cells, can be aberrantly expressed on the plasma membrane of various malignant cells, including those from brain tumors (e.g., glioblastoma), melanoma, and certain carcinomas. By targeting this tumor-associated antigen, pritumumab aims to either directly inhibit tumor cell migration and metastasis, induce antibody-dependent cellular cytotoxicity (ADCC), or potentially deliver a cytotoxic payload if used in a conjugated format.